Lanean...
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose
BACKGROUND: In the era of molecularly targeted agents (MTAs), it is recommended to account for toxicity over several cycles to identify the recommended phase II dose (RP2D). We investigated the relationship between the risk of toxicity at cycle 1 and the cumulative incidence of toxicity over subsequ...
Gorde:
| Argitaratua izan da: | J Natl Cancer Inst |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855968/ https://ncbi.nlm.nih.gov/pubmed/30838405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz024 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|